PODCAST

Targeted Therapies: A Paradigm Shift in RCC

Interviewed by Ron Piana | June 8, 2010

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Dr. Motzer has led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical studies. His research has helped identify three targeted antiangiogenesis drugs -- sunitinib (Sutent), temsirolimus (Torisel), and everolimus (Afinitor), as effective first- or second-line treatments for patients with advanced kidney cancer.

Robert J. Motzer, MD

AUDIO:

Right-click to download MP3

Robert J. Motzer, MD

AUDIO:

Right-click to download MP3

Coming up: Dr. Motzer gives his expert perspective on ASCO sessions and abstracts focusing on renal cell carcinoma…also watch for coverage highlights in gastrointestinal cancers, both colorectal and non-colorectal cancers, and special guest Editor Samuel M. Silver, MD, PhD, highlighting sessions on hematological malignancies.

by Gregory Pawelski | December 22, 2010 9:35 AM EST

In cancer medicine, it's not a case of throwing targeted drugs at the problem, it's knowing "what"targeted drugs and "how" to use them in "individual patients (not average populations).

The barrier to entry (FDA approval) is much lower in renal cell cancer with numerous targeted therapies now approved for a relatively small niche indication, including Nexavar (sorafenib), Sutent (sunitinib), Torisel (temsirolimus), Afinitor (everolimus), Votrient (pazopanib) and Avastin (bevacizumab).

Scientists involved with "real time" cell function analysis, which simultaneously measures direct antitumor activity and antivascular activity, prospectively, on fresh "live" human cancer cells, have found that Avastin may facilitate vascular access of Torisel (temsirolimus).

There are so many excellent agents for renal cell cancer (a bad actor type of cancer, when advanced), but with mass confusion for oncologists in knowing how to use them, cell-based funcitonal profiling can be very helpful.

by carlos Zeckler | November 23, 2010 12:58 AM EST

Financial Information?
Please editors of Cancernetwork.com, if you are going to publish comments and therapy dialogue with a respected Md, Robert J. Motzer, MD, PUBLISH CLEARLY THE FINANCIAL RELATIONSHIPS WITH THE MD and any drug companies!
I do not see any disclosures in the article, and as a matter of transparency, this is a critical disclosure. Does the Md receive(d) any form of compensation the makers of the drugs being discussed/ recommended by Dr Motzer?

Transparency and clarity of the presenters is vital in analyzing the information given, just as it would be if this were a financial broker discussing and recommending particular stock? Agreed?

ASCO 2010 Renal Cell Carcinoma

ASCO 2010: Selected Sessions in Renal Cell Carcinoma

Targeted Therapies: A Paradigm Shift in RCC

New Generation of Targeted Therapies Show Promise in RCC

At Increased Cost, Robotic Partial Nephrectomy Improves Kidney Cancer Outcomes
May 7, 2013

FDA Panel Votes 'No' on Tivozanib for Renal Cancer
May 3, 2013

Small Kidney Tumors Potentially Dangerous, Worth Treating
April 19, 2013

Serum Assay Composed of Trio of Biomarkers May Help Detect Kidney Cancers
April 18, 2013

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

SEARCH MEDICA RX

Browse drugs by name:

All

Search for drugs:

FROM PHYSICIANS PRACTICE

Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND, May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.

VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri, May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?

Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC, May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.

Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson, May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.

Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker, May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.

Targeted Therapies: A Paradigm Shift in RCC

Join the Conversation